Gilead Sciences' Kite Pharma has mapped out another route to the development of allogeneic or 'off-the-shelf' cell therapies for cancer, using technology developed by Appia Bio, a US startup ...

In 2018, the former leadership of team from Kite Pharma founded Allogene ... "In comparison to autologous CARTs, allo-CART, or ‘off-the-shelf’ CART therapies have a unique advantage in ...